Cost-efficacy of Knee Cartilage Defect Treatments in the United States

Background: Multiple knee cartilage defect treatments are available in the United States, although the cost-efficacy of these therapies in various clinical scenarios is not well understood. Purpose/Hypothesis: The purpose was to determine cost-efficacy of cartilage therapies in the United States wit...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of sports medicine 2020-01, Vol.48 (1), p.242-251
Main Authors: Everhart, Joshua S., Campbell, Andrew B., Abouljoud, Moneer M., Kirven, J. Caid, Flanigan, David C.
Format: Article
Language:English
Subjects:
Cartilage
Defects
Knee
Sports medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Multiple knee cartilage defect treatments are available in the United States, although the cost-efficacy of these therapies in various clinical scenarios is not well understood. Purpose/Hypothesis: The purpose was to determine cost-efficacy of cartilage therapies in the United States with available mid- or long-term outcomes data. The authors hypothesized that cartilage treatment strategies currently approved for commercial use in the United States will be cost-effective, as defined by a cost 3 cm2 to 36.0 for OCA of bipolar lesions. Failure rates ranged from 3 cm2 ($127,782) became cost-ineffective over 10 years. Conclusion: Currently employed treatments for knee cartilage defects in the United States are cost-effective in most clinically acceptable applications. Microfracture is not a cost-effective initial treatment of defects >3 cm2. OCA transplantation of the patella or bipolar lesions is potentially cost-ineffective and should be used judiciously.
ISSN:0363-5465
1552-3365
DOI:10.1177/0363546519834557